SCHEMBL20599741

SCHEMBL20599741

O=C1NCc2cc(B(O)O)ccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.48
CA9 Q16790 1/20 0.48
GRM5 P41594 4/20 0.47
GSK3B P49841 3/20 0.45
CLK4 Q9HAZ1 2/20 0.45
NTRK1 P04629 2/20 0.45
FLT3 P36888 2/20 0.45
DAPK3 O43293 1/20 0.45
PIM1 P11309 1/20 0.45
ROCK1 Q13464 1/20 0.45
PRF1 P14222 2/20 0.43
SMYD3 Q9H7B4 1/20 0.42
MKNK1 Q9BUB5 3/20 0.41
PRKCI P41743 1/20 0.40
NTRK2 Q16620 2/20 0.40
TYRO3 Q06418 1/20 0.40
DYRK1B Q9Y463 1/20 0.40
JAK2 O60674 1/20 0.39
MET P08581 1/20 0.39
FGFR1 P11362 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29956179 1.00 CA12 (0.48) CA12CA9GRM5GSK3BCLK4
SCHEMBL23757293 0.86 CLK4 (0.51) CA12CA9GRM5GSK3BCLK4
SCHEMBL14847348 0.83 CLK4 (0.51) CA12CA9GRM5GSK3BCLK4
SCHEMBL2562600 0.83 PARP10 (0.58) GRM5PARP1
SCHEMBL14847333 0.83 GSK3B (0.58) GRM5GSK3BCLK4NTRK1FLT3
SCHEMBL15962134 0.83 CLK4 (0.54) GRM5GSK3BCLK4NTRK1FLT3
SCHEMBL14847331 0.80 GSK3B (0.45) GRM5GSK3BCLK4NTRK1FLT3
SCHEMBL15962138 0.77 CLK4 (0.54) GSK3BCLK4NTRK1FLT3DAPK3
SCHEMBL14847350 0.77 GSK3B (0.54) GRM5GSK3BCLK4NTRK1FLT3
SCHEMBL18705768 0.76 PRF1 (0.39) CA12CA9GRM5GSK3BCLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4476204-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS Theras, Inc. (US) 2024-12-18 EP disclosed
CN-118946555-A Compounds having T-structures formed by at least four rings for use in the treatment of cancer and other indications 瑟拉斯有限公司 2024-11-12 CN disclosed
WO-2023154282-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2023-08-17 WO disclosed
WO-2023154282-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2023-08-17 WO disclosed
EP-3644991-A1 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR Merck Sharp & Dohme Corp. (US) 2020-05-06 EP disclosed
WO-2019005588-A1 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR MERCK SHARP & DOHME CORP. (US) 2019-01-03 WO disclosed
WO-2019000237-A1 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR MERCK SHARP & DOHME CORP. (US) 2019-01-03 WO disclosed